1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Novel Substrate-Inspired Fluorescence-Based Albumin Detection Improves Assessment of Clinical Outcomes in Hemodialysis Patients Receiving a Nursing Nutrition Intervention

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Albumin level does not precisely reflect nutritional status. We aimed to investigate the impact of a nutrition intervention on hemodialysis patients by use of fluorescence-based plasma albumin (FPA) detection.

          Material/Methods

          Eighty patients underwent maintenance hemodialysis for more than half a year and had a mean albumin <3.5 g/dL for over 3 months. The subjects were randomly divided into either a Control Group (CG) or an Intervention Group (IG). The IG received nutritional supplementation, and the CG group received routine nutritional support for 12 months. FPA and plasma albumin (PA) concentrations were measured. The fluorescence probe 1,3-Dichloro-7-hydroxy-9,9-dimethyl-2(9H)-acridone methyl biphenyl benzoate was used in FPA detection. Quality of life was estimated using WHOQOL-BREF (Quality of Life Scale developed through the World Health Organization), the 36-Item Short-Form Survey (SF-36), and the 6-minute walking test (6MWT).

          Results

          After a 6-month and a 12-month intervention, PA and FPA concentrations increased, and the increase in FPA concentration was higher than that of PA in the IG group ( P<0.05). Comparatively, the parameters of quality of life and 6MWT were improved in the IG group ( P<0.05) but there were only minor changes in the CG group ( P>0.05). There is an obvious association between the changes in FPA concentration and the parameters of quality of life and 6MWT but not PA.

          Conclusions

          Use of the fluorescence probe improves the detection sensitivity of plasma albumin and provides a potential method to assess clinical outcomes in hemodialysis patients.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Sample size calculation

          INTRODUCTION One of the pivotal aspects of planning a clinical study is the calculation of the sample size. It is naturally neither practical nor feasible to study the whole population in any study. Hence, a set of participants is selected from the population, which is less in number (size) but adequately represents the population from which it is drawn so that true inferences about the population can be made from the results obtained. This set of individuals is known as the “sample.” In a statistical context, the “population” is defined as the complete set of people (e.g., Indians), the “target population” is a subset of individuals with specific clinical and demographic characteristics in whom you want to study your intervention (e.g., males, between ages 45 and 60, with blood pressure between 140 mmHg systolic and 90 mmHg diastolic), and “sample” is a further subset of the target population which we would like to include in the study. Thus a “sample” is a portion, piece, or segment that is representative of a whole. ATTRIBUTES OF A SAMPLE Every individual in the chosen population should have an equal chance to be included in the sample. Ideally, choice of one participant should not affect the chance of another's selection (hence we try to select the sample randomly – thus, it is important to note that random sampling does not describe the sample or its size as much as it describes how the sample is chosen). The sample size, the topic of this article, is, simply put, the number of participants in a sample. It is a basic statistical principle with which we define the sample size before we start a clinical study so as to avoid bias in interpreting results. If we include very few subjects in a study, the results cannot be generalized to the population as this sample will not represent the size of the target population. Further, the study then may not be able to detect the difference between test groups, making the study unethical. On the other hand, if we study more subjects than required, we put more individuals to the risk of the intervention, also making the study unethical, and waste precious resources, including the researchers’ time. The calculation of an adequate sample size thus becomes crucial in any clinical study and is the process by which we calculate the optimum number of participants required to be able to arrive at ethically and scientifically valid results. This article describes the principles and methods used to calculate the sample size. Generally, the sample size for any study depends on the:[1] Acceptable level of significance Power of the study Expected effect size Underlying event rate in the population Standard deviation in the population. Some more factors that can be considered while calculating the final sample size include the expected drop-out rate, an unequal allocation ratio, and the objective and design of the study.[2] LEVEL OF SIGNIFICANCE Everyone is familiar with the “p” value. This is the “level of significance” and prior to starting a study we set an acceptable value for this “p.” When we say, for example, we will accept a p<0.05 as significant, we mean that we are ready to accept that the probability that the result is observed due to chance (and NOT due to our intervention) is 5%. To put it in different words, we are willing to accept the detection of a difference 5 out of 100 times when actually no difference exists (i.e., get a “false positive” result). Conventionally, the p value of 5% (p = 0.05) or 1% (p = 0.01), which means 5% (or 1%) chance of erroneously reporting a significant effect is accepted. POWER Sometimes, and exactly conversely, we may commit another type of error where we fail to detect a difference when actually there is a difference. This is called the Type II error that detects a false negative difference, as against the one mentioned above where we detect a false positive difference when no difference actually exists or the Type I error. We must decide what is the false negative rate we are willing to accept to make our study adequately powered to accept or reject our null hypothesis accurately. This false negative rate is the proportion of positive instances that were erroneously reported as negative and is referred to in statistics by the letter β. The “power” of the study then is equal to (1 –β) and is the probability of failing to detect a difference when actually there is a difference. The power of a study increases as the chances of committing a Type II error decrease. Usually most studies accept a power of 80%. This means that we are accepting that one in five times (that is 20%) we will miss a real difference. Sometimes for pivotal or large studies, the power is occasionally set at 90% to reduce to 10% the possibility of a “false negative” result. EXPECTED EFFECT SIZE We can understand the concept of “effect size” from day-to-day examples. If the average weight loss following one diet program is 20 kg and following another is 10 kg, the absolute effect size would be 10 kg. Similarly, one can claim that a specific teaching activity brings about a 10% improvement in examination scores. Here 10 kg and 10% are indicators of the claimed effect size. In statistics, the difference between the value of the variable in the control group and that in the test drug group is known as effect size. This difference can be expressed as the absolute difference or the relative difference, e.g., in the weight loss example above, if the weight loss in the control group is 10 kg and in the test group it is 20 kg, the absolute effect size is 10 kg and the relative reduction with the test intervention is 10/20, or 50%. We can estimate the effect size based on previously reported or preclinical studies. It is important to note that if the effect size is large between the study groups then the sample size required for the study is less and if the effect size between the study groups is small, the sample size required is large. In the case of observational studies, for example, if we want to find an association between smoking and lung cancer, since earlier studies have shown that there is a large effect size, a smaller sample would be needed to prove this effect. If on the other hand we want to find out the association between smoking and getting brain tumor, where the “effect” is unknown or small, the sample size required to detect an association would be larger. UNDERLYING EVENT RATE IN THE POPULATION The underlying event rate of the condition under study (prevalence rate) in the population is extremely important while calculating the sample size. This unlike the level of significance and power is not selected by convention. Rather, it is estimated from previously reported studies. Sometimes it so happens that after a trial is initiated, the overall event rate proves to be unexpectedly low and the sample size may have to be adjusted, with all statistical precautions. STANDARD DEVIATION (SD OR Σ) Standard deviation is the measure of dispersion or variability in the data. While calculating the sample size an investigator needs to anticipate the variation in the measures that are being studied. It is easy to understand why we would require a smaller sample if the population is more homogenous and therefore has a smaller variance or standard deviation. Suppose we are studying the effect of an intervention on the weight and consider a population with weights ranging from 45 to 100 kg. Naturally the standard deviation in this group will be great and we would need a larger sample size to detect a difference between interventions, else the difference between the two groups would be masked by the inherent difference between them because of the variance. If on the other hand, we were to take a sample from a population with weights between 80 and 100 kg we would naturally get a tighter and more homogenous group, thus reducing the standard deviation and therefore the sample size. SAMPLE SIZE CALCULATION There are several methods used to calculate the sample size depending on the type of data or study design. The sample size is calculated using the following formula: n   =   2 Z a + Z 1 – β 2 σ 2 , Δ 2 where n is the required sample size. For Zα, Z is a constant (set by convention according to the accepted α error and whether it is a one-sided or two-sided effect) as shown below: α-error 5% 1% 0.1% 2-sided 1.96 2.5758 3.2905 1-sided 1.65 2.33 For Z1-,β,Z is a constant set by convention according to power of the study as shown below: Power 80% 85% 90% 95% Value 0.8416 1.0364 1.2816 1.6449 In the above-mentioned formula σ is the standard deviation (estimated) and Δ the difference in effect of two interventions which is required (estimated effect size). This gives the number of sample per arm in a controlled clinical trial. EXAMPLE This issue of the Journal has an article describing the benefits of ayurvedic treatment AyTP in patients of migraine in an open uncontrolled trial design.[3] If anyone wishes to confirm these results using a randomized controlled trial design where the effect of the ayurvedic intervention will be compared to standard of care in headache as measured by VAS how would we plan the sample size? As seen above, we need the following values: Z α, Z 1-β,σ, standard deviation (estimated), and Δ, the difference in effect of two interventions. Let us assume we will accept a p<0.05 as acceptable and a study with 80% power; using the above tables, we get the following values: Z α, is 1.96 (in this case we will be using a two-tailed test because the results could be bidirectional). Z 1-β, is 0.8416. The standard deviation (based on the data in the published paper) would be approximately 0.7. For Δ, the paper describes that the ayurvedic therapy has given a 35% effect. Previously it has been reported that sumatriptan at 50 mg improves headache by 50%.[4] Thus, the effect size would be 15% (i.e., 0.15). The sample size for the new study will be n = 2 1 . 96 + 0 . 8416 2 0 . 72 2 0 . 15 2 = 362 per arm. Calculating for a 10% drop-out rate one would need to complete approximately 400 patients per arm to be able to say with any degree of confi dence whether a difference exists between the two treatments. LIMITATIONS OF THE CALCULATED SAMPLE SIZE The sample size calculated using the above formula is based on some conventions (Type I and II errors) and few assumptions (effect size and standard variation). The sample size ALWAYS has to be calculated before initiating a study and as far as possible should not be changed during the study course. The sample size calculation is also then influenced by a few practical issues, e.g., administrative issues and costs.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Systematic FTIR Spectroscopy Study of the Secondary Structure Changes in Human Serum Albumin under Various Denaturation Conditions

            Human serum albumin (HSA) is the most abundant protein in blood plasma. HSA is involved in the transport of hormones, fatty acids, and some other compounds, maintenance of blood pH, osmotic pressure, and many other functions. Although this protein is well studied, data about its conformational changes upon different denaturation factors are fragmentary and sometimes contradictory. This is especially true for FTIR spectroscopy data interpretation. Here, the effect of various denaturing agents on the structural state of HSA by using FTIR spectroscopy in the aqueous solutions was systematically studied. Our data suggest that the second derivative deconvolution method provides the most consistent interpretation of the obtained IR spectra. The secondary structure changes of HSA were studied depending on the concentration of the denaturing agent during acid, alkaline, and thermal denaturation. In general, the denaturation of HSA in different conditions is accompanied by a decrease in α-helical conformation and an increase in random coil conformation and the intermolecular β-strands. Meantime, some variation in the conformational changes depending on the type of the denaturation agent were also observed. The increase of β-structural conformation suggests that HSA may form amyloid-like aggregates upon the denaturation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Malnutrition, inflammation, progression of vascular calcification and survival: Inter-relationships in hemodialysis patients

              Background and aims Malnutrition and inflammation are closely linked to vascular calcification (VC), the severity of which correlate with adverse outcome. However, there were few studies on the interplay between malnutrition, inflammation and VC progression, rather than VC presence per se. We aimed to determine the relationship of malnutrition, inflammation, abdominal aortic calcification (AAC) progression with survival in hemodialysis (HD) patients. Methods Malnutrition and inflammation were defined as low serum albumin (< 40 g/L) and high hs-CRP (≥ 28.57 nmol/L), respectively. We defined AAC progression as an increase in AAC score using lateral lumbar radiography at both baseline and one year later. Patients were followed up to investigate the impact of AAC progression on all-cause and cardiovascular mortality. Results AAC progressed in 54.6% of 97 patients (mean age 58.2±11.7 years, 41.2% men) at 1-year follow-up. Hypoalbuminemia (Odds ratio 3.296; 95% confidence interval 1.178–9.222), hs-CRP (1.561; 1.038–2.348), low LDL-cholesterol (0.976; 0.955–0.996), and the presence of baseline AAC (10.136; 3.173–32.386) were significant risk factors for AAC progression. During the mean follow-up period of 5.9 years, 38(39.2%) patients died and 27(71.0%) of them died of cardiovascular disease. Multivariate Cox regression analysis adjusted for old age, diabetes, cardiovascular history, and hypoalbuminemia determined that AAC progression was an independent predictor of all-cause mortality (2.294; 1.054–4.994). Conclusions Malnutrition and inflammation were significantly associated with AAC progression. AAC progression is more informative than AAC presence at a given time-point as a predictor of all-cause mortality in patients on maintenance HD.
                Bookmark

                Author and article information

                Journal
                Med Sci Monit
                Med Sci Monit
                Medical Science Monitor
                Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
                International Scientific Literature, Inc.
                1234-1010
                1643-3750
                2021
                10 August 2021
                22 April 2021
                : 27
                : e930257-1-e930257-13
                Affiliations
                Blood Purification Center, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, PR China
                Author notes
                Corresponding Author: Wenhong Wang, e-mail: 13591355825@ 123456163.com
                [A]

                Study Design

                [B]

                Data Collection

                [C]

                Statistical Analysis

                [D]

                Data Interpretation

                [E]

                Manuscript Preparation

                [F]

                Literature Search

                [G]

                Funds Collection

                [*]

                Lei You and Xia Wang contributed equally to this work

                Article
                930257
                10.12659/MSM.930257
                8364288
                34375323
                2a135f6e-dbef-4a03-b986-925f965cbf0e
                © Med Sci Monit, 2021

                This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International ( CC BY-NC-ND 4.0)

                History
                : 04 December 2020
                : 09 March 2021
                Categories
                Clinical Research

                fluorescent antibody technique, direct,hemodialysis solutions,nutrition assessment,serum albumin

                Comments

                Comment on this article